Affymax and Takeda Announce Permanent J-Code for OMONTYS(R …

Published January 3, 2013

Affymax and Takeda Announce Permanent J-Code for OMONTYS(R …

Filed under: drug treatment centers in california

DEERFIELD, Ill., Jan 03, 2013 (BUSINESS WIRE) — Affymax, Inc. (NASDAQ:AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for OMONTYS(R) (peginesatide …
Read more on MarketWatch (press release)

A Call to Eliminate 'Chemotherapy Concession'

Filed under: drug treatment centers in california

A new study confirms that financial incentives exist for some US oncologists in the prescribing of chemotherapy and growth factors for treatment-related anemia. These potential "inducements" are not widespread, existing for only about 25% of …
Read more on Medscape

CytRx Promotes Dr. Daniel Levitt to Executive Vice President

Filed under: drug treatment centers in california

There is no doubt that we are benefiting from his extensive senior management experience, his prior success in piloting drug programs through the clinical and regulatory processes, seven of which have received marketing approval, and his credibility …
Read more on PharmiWeb.com (press release)